BIRC2 and chronic myelogenous leukemia, BCR-ABL1 positive: IAP inhibitors/SMAC mimetic drugs (ex: LCL161) target the antiapoptotic IAP molecules including cIAP1, cIAP2, and survivin and have shown potential activity in CML as a monotherapy and in combination with TKI [47–49].